rosuvastatin + placebo + rosuvastatin + atorvastatin
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Dyslipidemia
Conditions
Dyslipidemia, Acute Coronary Syndromes
Trial Timeline
Apr 1, 2006 → Sep 1, 2007
NCT ID
NCT00665834About rosuvastatin + placebo + rosuvastatin + atorvastatin
rosuvastatin + placebo + rosuvastatin + atorvastatin is a approved stage product being developed by AstraZeneca for Dyslipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00665834. Target conditions include Dyslipidemia, Acute Coronary Syndromes.
What happened to similar drugs?
14 of 20 similar drugs in Dyslipidemia were approved
Approved (14) Terminated (3) Active (4)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00665834 | Approved | Completed |
Competing Products
20 competing products in Dyslipidemia